Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
FIBROSARC did not meet its primary PFS endpoint in the final analysi
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Subscribe To Our Newsletter & Stay Updated